What Is Average Weight Loss on Zepbound?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide) is a dual-action GLP-1 and GIP receptor agonist that has shown exceptional results in clinical studies. Patients using Zepbound typically lose between 15 and 22 percent of their starting body weight when combined with lifestyle modifications. Understanding these average outcomes can help you set realistic expectations for your own weight loss journey.

How Much Weight Do Zepbound Users Lose on Average?

The SURMOUNT-1 clinical trial, which evaluated tirzepatide efficacy over 68 weeks, found that participants receiving the highest dose lost an average of 22.5 percent of their body weight. Participants at lower doses achieved reductions of 15 to 20 percent. These results represent a significant advantage compared to earlier GLP-1 medications like semaglutide, which typically produced 10 to 15 percent weight loss. Individual outcomes vary based on starting weight, metabolism, adherence to injection schedule, and diet and exercise habits.

It is important to note that Zepbound results are not permanent without ongoing medication use. Clinical evidence indicates that weight regain occurs when patients discontinue tirzepatide, which is why many healthcare providers recommend long-term therapy for sustained weight management. PlexusDx compounded tirzepatide injection maintains the same active ingredient as brand-name Zepbound, delivering identical clinical outcomes at a flat monthly rate starting at $249.

Tirzepatide vs. Semaglutide: Which Produces Greater Weight Loss?

Head-to-head comparison data demonstrates that tirzepatide outperforms semaglutide across most weight loss metrics. In the SURMOUNT-4 trial, tirzepatide achieved 21 percent average weight reduction, while semaglutide (Wegovy) achieved approximately 17 percent reduction at maximum approved doses. This 4-percentage-point advantage reflects tirzepatide's unique dual mechanism: it activates both GLP-1 and GIP receptors, whereas semaglutide targets only the GLP-1 receptor. The GIP pathway adds an additional appetite-suppression signal and may enhance metabolic rate.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Factors That Influence Your Personal Weight Loss Outcomes

Not every patient achieves the same weight loss percentage, even when taking identical tirzepatide doses. Genetic factors play a significant role: carriers of the GLP1R rs6923761 variant may experience stronger appetite suppression, while variants in the FTO gene (rs9939609) influence baseline metabolic rate and hunger signaling. Diet quality, daily step count, sleep duration, stress levels, and baseline insulin resistance all modify the medication's effectiveness. Patients who combine tirzepatide with structured nutrition counseling and regular physical activity consistently outperform those relying on medication alone.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Zepbound or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Realistic Timeline: When Do Zepbound Results Appear?

Most patients notice appetite suppression and reduced food cravings within the first 1 to 2 weeks of starting tirzepatide injections. Measurable weight loss typically becomes apparent on the scale within 2 to 4 weeks, though initial losses may include both fat and water weight. The most significant reductions occur between weeks 8 and 24 as the medication reaches steady-state and doses are optimized. By week 16, many patients have lost 5 to 10 percent of their starting weight; by week 52, losses of 15 to 20 percent are common.

Dose escalation follows a gradual schedule: most providers begin at a low dose (2.5 mg weekly for tirzepatide) and increase by 2.5 mg every 4 weeks until reaching an effective maintenance dose or the patient's maximum tolerated dose. This titration approach minimizes gastrointestinal side effects while maximizing weight loss. PlexusDx structures tirzepatide injections at a flat monthly price ($289 per month minimum), meaning your dose can increase without increasing your cost. Your dose may need to go up. Your price won't.

What Happens After You Stop Taking Tirzepatide?

Clinical follow-up data reveals that weight regain occurs rapidly after tirzepatide discontinuation. Patients who stopped treatment in SURMOUNT trials regained approximately 50 percent of their lost weight within one year. This outcome is not a failure of the medication; rather, it reflects the chronic nature of metabolic dysfunction and obesity. Tirzepatide works by recalibrating appetite signals and improving insulin sensitivity—benefits that persist only while the medication is active in your system.

Many patients and providers view tirzepatide as a long-term maintenance therapy similar to blood pressure or cholesterol medications. Sustained weight loss requires sustained treatment. Some patients transition to lower maintenance doses once they reach their goal weight, allowing them to stabilize results while reducing monthly costs. PlexusDx compounded tirzepatide injection is available without insurance and without membership fees, making extended therapy financially accessible across all 50 states. HSA and FSA funds are eligible for payment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is 15-22% weight loss typical for everyone taking Zepbound?

No. While clinical trials show an average of 15-22% weight loss, individual results vary widely based on genetics, lifestyle adherence, starting weight, and dose tolerance. Some patients lose 10%, others exceed 25%. PlexusDx Precision Peptide Genetic Testing can identify your genetic predisposition to tirzepatide response and recommend personalized dosing strategies.

How does tirzepatide's weight loss compare to older GLP-1 medications?

Tirzepatide outperforms semaglutide by approximately 4-5 percentage points in clinical trials (21% vs. 17% average reduction). This advantage comes from tirzepatide's dual GLP-1/GIP receptor activation, which provides stronger appetite suppression and may boost metabolic rate compared to single-pathway GLP-1 medications.

Can I afford long-term tirzepatide treatment with PlexusDx?

Yes. PlexusDx compounded tirzepatide injection costs $289 per month flat across all dose levels—no per-dose markup, no membership fee, and HSA/FSA eligible. All medications are sourced from licensed 503A compounding pharmacies and available in all 50 states without insurance requirements.

What are the most common side effects during Zepbound treatment?

Nausea, vomiting, diarrhea, and constipation are most frequent, especially during dose escalation. These effects typically diminish within 1-2 weeks and often improve with dietary adjustments. Serious complications are rare when doses are escalated gradually. Discuss any persistent symptoms with your healthcare provider to optimize your tolerance.

How does the Precision Peptide Genetic Test improve my Zepbound results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Average Weight Loss On Ozempic
• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Maxlife Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.